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Purpose: The purpose of this study is to analyze the dose response of the mammalian target of 
rapamycin (mTOR) inhibitor, rapamycin, on tumor burden and hypoxia, and study the treatment 
effect on vasculature in LHBETATAG retinal tumors.
Methods: This study was approved by the Institutional Animal Care and Use Committee and 
follows Association for Research in Vision and Ophthalmology guidelines.   Eighteen-week-old 
LHBETATAG retinal tumor eyes (n = 30) were evaluated. Mice were divided into five groups 
and received periocular injections once weekly for two consecutive weeks of: a) 80% DMSO 
(dimethyl sulfoxide, vehicle control), b) 0.00333 mg/kg, c) 0.167 mg/kg, d) 3.33 mg/kg, and 
e) 6.67 mg/kg of rapamycin. Tumor sections were analyzed for hypoxia, tumor burden, and 
vasculature with immunohistochemistry techniques.
Results: Reduction in tumor burden and hypoxia was significantly different between rapamycin 
doses and control (P , 0.002). Eyes treated with rapamycin at 0.167, 3.33, and 6.67 mg/kg 
showed a significant decrease in tumor burden in comparison with the vehicle control group 
(P = 0.019, P = 0.001, P = 0.009, respectively) and the 0.00333 mg/kg dose response (P = 0.023, 
P = 0.001, P = 0.010, respectively). Eyes treated with rapamycin at 3.33 mg/kg showed a sig-
nificant reduction in the amount of hypoxia in comparison with the lower concentration groups 
(0.00333 and 0.167 mg/kg) of rapamycin (P = 0.024 and P = 0.052, respectively). The number 
of mature vessels was significantly lower in the 3.33 mg/kg treated versus vehicle control 
(P = 0.015; equal variances assumed, t-test for equality of means). The number of neovessels 
was not significantly different between both groups (P = 0.092).
Conclusion: Inhibition of mTOR was shown to reduce tumor burden, hypoxia, and vasculature 
in the LHBETATAG retinoblastoma tumor model. Rapamycin may have a role in combination with 
chemotherapy or other adjuvant therapies to enhance retinoblastoma tumor control.
Keywords: rapamycin, mTOR, hypoxia, retinoblastoma, anaerobic glycolysis
Introduction
Retinoblastoma is the most common primary intraocular malignancy in children.1,2 
Associated risks of retinoblastoma include metastatic disease, choroidal invasion, and 
neovascularization.3–5 More than 95% long-term survival rates in the United States 
and other developed countries have led to a research focus on local tumor control 
and globe conservation with preservation of sight. However, present treatments 
(eg, chemotherapy) result in noteworthy complications including, but not limited to, 
  neutropenia, anemia, thrombocytopenia, infections, and risk for second malignancies 
(eg, acute myeloid leukemia).6 Enucleation is generally performed in about 20% of 
the cases of intraocular retinoblastoma due to advanced disease.3,7Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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The serine–threonine kinase, mammalian target of 
rapamycin (mTOR), assumes a key regulatory role in 
cell growth and angiogenesis through effects on cellular 
  metabolism and protein translation. Upstream, mTOR is 
activated by PI3K/Akt signaling, which has been shown to be 
dysregulated in cancer cells.8,9 As a result, enhanced mTOR 
activity leads to altered cellular signaling, mediated through 
the downstream targets such as p70S6K. This pathway has 
recently been shown to be O2-sensitive. Hypoxia-induced 
proliferation of adventitial fibroblast was demonstrated to 
require the activation of mTOR.10 Other studies have shown 
the effects of mTOR inhibition resulting in a reduction of 
numerous downstream targets including glucose transporter 
(GLUT)-1, vascular endothelial growth factor (VEGF), 
and hypoxia inducible factor (HIF)-1α.11,12 Notably, cell 
proliferation and retinoblastoma (Rb) protein suppression 
concomitantly inhibited the mTOR pathway.13
mTOR as an upstream regulator of HIF, a   transcription 
factor that promotes protein production and glycolytic 
enzymes and transporters involved in glucose uptake under 
hypoxic conditions, plays a key role in the metabolic shift 
from oxidative phosphorylation to anaerobic glycolysis.11,12,14 
Hypoxic retinoblastoma cells survive under low O2 tension 
conditions, which are most prevalent during advanced tumor 
development.15 These cells have been shown to be resistant 
to chemotherapy and radiation, which specifically target the 
rapidly dividing cells.16 Hypoxic cells, therefore, may not 
respond to conventional treatments.15,17 These cells rely on 
anaerobic glycolysis for adenosine triphosphate (ATP) pro-
duction and survival, which is a significantly less efficient 
method than oxidative phosphorylation in generating energy 
from glucose. We have previously shown that hypoxic cells 
can be targeted by inhibiting aspects of cellular metabolism. 
Using the glycolytic inhibitor 2-deoxy-D-glucose (2-DG), 
tumor burden was significantly reduced while effectively 
decreasing the amount of intratumoral hypoxia in LHBETATAG 
retinal tumors.15,16,18–20
Novel therapeutic strategies are lacking to effectively 
control retinoblastoma without the use of systemic chemo-
therapy, radiation, or enucleation.21–23 With mTOR potentially 
being an O2-sensitive pathway that cells may utilize to adapt 
to harsh tumor microenvironments, treatment with the mTOR 
inhibitor, rapamycin, may provide a viable mode to modulate 
the killing of the chemo-resistant hypoxic cell population in 
LHBETATAG retinal tumors. The purposes of this study are to: 
1) analyze the dose response of rapamycin on tumor burden 
and hypoxia in LHBETATAG retinal tumors, and 2) study the 
treatment effect on vasculature in these retinal tumors.
Materials and methods
LhBeTATAg mouse model for retinoblastoma
The study protocol was approved by the University of 
Miami Institutional Animal Care and Use Review Board 
Committee. The LHBETATAG transgenic mouse model used in 
this study has been characterized previously.24 This animal 
model develops bilateral multifocal retinal tumors that are 
stable and grow at a predictable rate (ie, tumor at 4 weeks 
is undetectable, at 8 weeks is small, at 12 weeks is medium, 
and at 16 weeks is large).25
subconjuctival injections of rapamycin
Eighteen-week-old LHBETATAG retinal tumor, right eyes, 
(n = 30) were treated and evaluated. Mice were divided into five 
groups and received periocular injections for two   consecutive 
weeks of: a) 80% dimethyl sulfoxide (DMSO, vehicle 
  control), b) 0.00333 mg/kg, c) 0.167 mg/kg, d) 3.33 mg/kg, 
and e) 6.67 mg/kg. Since rapamycin is   lipophilic and, thus, 
has a poor water solubility, all the dosages of rapamycin were 
diluted in 80% DMSO. A total volume of 20 µL was admin-
istered in each injection. Treatment of   rapamycin was given 
once a week, starting at 16 weeks of age. Eyes were enucleated 
at 1 week following the last treatment. To assess hypoxia, 
mice received 60 mg/kg of pimonidazole via   intraperitoneal 
injection. Mice were euthanized with CO2 fumes and eyes 
were enucleated. Tumor sections were analyzed for hypoxia, 
tumor burden, and vasculature.
Tumor burden measurements
Eyes were sectioned serially and processed for standard 
hematoxylin-eosin (H&E) staining. Microscopic images 
of H&E-stained sections (50 8-µm sections per eye) were 
obtained with a digital camera at a magnification of 40×. 
The section of the eye containing the largest cross-sectional 
tumor area was chosen for analysis. Tumor boundaries were 
traced using imaging software (Image Pro Express Software; 
Media Cybernetics, Silver Spring, MD). Tumor areas for all 
eyes were averaged, yielding an average area for each group. 
Tumor burden was averaged, yielding an average area for 
each group. Tumor burden was expressed as the tumor/globe 
ratio by dividing the tumor area by the area of the globe to 
normalize the data as previously described.26
Measuring hypoxic regions
To assess tumor hypoxia after treatment, LHBETATAG mice 
were injected intraperitoneally with a 0.16 mL   suspension of 
pimonidazole (a drug used to detect hypoxia that penetrates 
all tissues, including the brain). This   suspension consisted Clinical Ophthalmology 2011:5
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Figure 1 Percentage of tumor burden following different doses of treatment with 
rapamycin alone. Tumor burden is significantly different between rapamycin doses 
(P , 0.002). eyes treated with rapamycin at 0.167, 3.33, and 6.67 mg/kg showed a 
significant decrease in tumor burden in comparison with the vehicle control group 
(P = 0.019, P = 0.001, P = 0.009, respectively) and the 0.00333 mg/kg dose response 
(P = 0.023, P = 0.001, P = 0.010, respectively). 
Note: *Denotes statistical significant percentage reduction from the vehicle control 
(80% DMsO). 
Abbreviation: DMsO, dimethyl sulfoxide.
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of 10 mg of pimonidazole hydrochloride (Chemicon, 
Temecula, CA) in 1 mL saline. Pimonidazole is known to 
bind to   thiol-containing proteins in cells under low oxygen 
(O2)   tension.27 These adducts can be detected with spe-
cific   antibodies and stained using   immunohistochemical 
  techniques. Animals were euthanized 2 hours after 
  pimonidazole injection, and eyes were harvested and 
  sectioned for histopathologic examination. Eyes were fixed 
with cold methanol for 10 minutes and immunostained with 
a directly labeled antibody recognizing pimonidazole adducts 
(Hypoxyprobe 1-Mab-1-FITC, clone 4.3.11.3; Chemicon) or 
the same concentration of a directly labeled isotype control 
antibody (mouse IgG1-FITC; Caltag, Burlingame, CA). 
Background signal intensities were minimal. All samples 
were normalized to intensities from isotype controls.
immunohistochemistry
Tumor samples were frozen in OCT (optimal cutting 
  temperature) compound immediately after enucleation, and 
serially sectioned (8 µm). Slides were fixed with methanol for 
10 minutes (−20°C) and immunohistochemical   analyses were 
performed. Mature vessels were detected with   alpha-smooth 
muscle actin (α-sma) Cy3 conjugate (1:3,000; Sigma   Chemical 
Co, St Louis, MO) which   specifically binds to pericytes.28 
Neovessels were detected with anti-endoglin (CD105 Wi, 
1:500; Abcam, Cambridge, MA), which has been shown to 
have specificity for endothelial cells   undergoing   angiogenesis.29 
Alexa Fluor 568 goat   anti-mouse and 488 donkey anti-mouse 
were used as   secondary   antibodies for anti-collagen type IV 
and endoglin, respectively (1:500; Invitrogen, Carlsbad, CA). 
Omission of the primary   antibody (secondary only) was used 
as a   negative control for   nonspecific binding. Cell nuclei were 
stained for 5 minutes with 4′,6′-diamidino-2-phenylindole 
(DAPI, 1:5,000;   Invitrogen, Carlsbad, CA).
image analysis
Serial cross-sections of eyes containing tumors were 
examined for the presence of the described markers with a 
BX51 Olympus upright fluorescence microscope (Olympus 
  American Inc., Melville, NY). All images were obtained at 
200× magnification using different filters for the DAPI, Alexa 
Fluor 488, and 568 signals.
Statistical methods
Analysis of variance followed by post hoc least-significant 
different tests was used to evaluate differences between 
treatment groups with respect to tumor burden and hypoxia. 
Differences in the number of new vessels and mature vessels 
between the vehicle control and the rapamycin treated group 
were evaluated by two sample t-test. Values were considered 
significant with P-values #0.05.
Results
Tumor growth is directly associated with advancing age in 
the LHBETATAG transgenic mouse model.30 We have previously 
shown that hypoxia is significantly detected in large-size 
LHBETATAG retinal tumors, and minimal hypoxia is observed 
in small LHBETATAG retinal tumors.15
To assess the impact of periocular administration of 
rapamycin on tumor burden and hypoxia, LHBETATAG mice 
were treated with varying dosages of this mTOR inhibitor. 
There was no apparent toxicity observed due to the drug 
at the doses used in the current study. There were highly 
significant differences between treatment doses for tumor 
burden and hypoxia (P , 0.001). Tumor burden was found 
to be significantly   different between rapamycin doses 
(P , 0.002) (Figures 1 and 2). Eyes treated with rapamycin 
at 0.167, 3.33, and 6.67 mg/kg showed a significant decrease 
in tumor   burden in comparison with the vehicle control 
group (P = 0.019, P = 0.001, P = 0.009, respectively) and 
the 0.00333 mg/kg dose response (P = 0.023, P = 0.001, 
P = 0.010, respectively). There was no difference between 
the lowest dose group (ie, 0.00333 mg/kg) and the vehicle 
control for tumor burden (P = 0.992).
The percentage of hypoxia is significantly different 
between the rapamycin doses (P , 0.002) (Figures 2 and 3). 
Eyes treated with rapamycin at 3.33 mg/kg showed a   significant 
decrease in the percentage of hypoxia in comparison with the Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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lower concentration groups (0.00333 and 0.167 mg/kg) of 
rapamycin (P = 0.024 and P = 0.052, respectively). There was 
no difference between the highest doses of rapamycin (3.33 
and 6.67 mg/kg) for the percentage of intratumoral hypoxia 
(P = 0.997). There is a significant correlation between tumor 
burden and the percentage of hypoxia (P , 0.001; Spearmen 
non-parametric correlation, r = 0.725).
To assess the impact of periocular administration of 
rapamycin on blood vessels, the amount of neovessels and 
mature vessels were analyzed for the rapamycin dose with the 
highest impact on the reduction of tumor burden and hypoxia 
(ie, 3.33 mg/kg). Blood vessels were broken down by   vessel 
caliber (ie, small and large).31 The percentage of mature 
  vessels was significantly lower in the rapamycin treated versus 
the vehicle control group (P = 0.015; equal variances assumed, 
t-test for equality of means) (Figures 4 and 5). The percent-
age of neovessels was not significantly different between the 
rapamycin treated and the vehicle control group (P = 0.092). 
This change was mainly due to the small-caliber blood vessels 
with a reduction of 41.1% for mature vessels versus 70.5% for 
neovessels compared with the vehicle control (P , 0.001). 
There were no significant changes for large-caliber vessels 
for neither neo- nor mature vessels compared with the vehicle 
control (101% and 54.7%, respectively).
Discussion
This study is the first to demonstrate that inhibition of mTOR 
significantly reduces hypoxia and tumor burden in LHBETATAG 
retinal tumors. Tumor cells thrive in a heterogeneous microen-
vironment that contains regions with low O2 tensions requiring 
neoplastic cells to adapt to hypoxic conditions as the tumor 
develops.15,17,32–34 In order to survive under hypoxia, metaboli-
cally active tumor cells alter their protein synthesis favoring 
enhanced anaerobic glucose metabolism. Additional stress 
80% DMSO
Hypoxia - 200X Dapi - 200X Tumor burden - 40X
0.00333 mg/kg
0.167 mg/kg
3.33 mg/kg
6.67 mg/kg
Figure  2  hypoxia  and  tumor  burden  reduction  following  different  doses  of 
rapamycin  treatment.  There  were  highly  significant  interactions  between  the 
treatment dose for tumor burden and hypoxia (P , 0.001). DAPi stain (blue) for all 
the cell nuclei and pimonidazole stain (green) for hypoxic regions. 
Abbreviations: DAPi, 4′,6′-diamidino-2-phenylindole; DMsO, dimethyl sulfoxide.
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Figure 3 reduction in the percentage of tumor hypoxia following different doses 
of treatment with rapamycin. The percentage of hypoxia is significantly different 
between the rapamycin doses (P , 0.002). eyes treated with rapamycin at 3.33 mg/kg 
showed a significant decrease in the percentage of hypoxia in comparison with the 
groups treated with 0.00333 and 0.167 mg/kg of rapamycin (P = 0.024 and P = 0.052, 
respectively).
Note: *Denotes statistical significant percentage difference in comparison with the 
groups treated with 0.00333 and 0.167 mg/kg. 
Abbreviation: DMsO, dimethyl sulfoxide.
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Figure 4 effect of rapamycin on the vasculature. neovessels and mature vessels 
were analyzed for the rapamycin dose with the highest impact on reducing tumor 
burden  and  hypoxia  (ie,  3.33  mg/kg).  The  percentage  of  mature  vessels  was 
significantly lower in the rapamycin treated versus the untreated group (P = 0.015), 
whereas the percentage of neovessels was not significantly different between the 
rapamycin treated and the control group (P = 0.092). 
Note: *Denotes statistical significant percentage reduction from the vehicle control 
(80% DMsO). 
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adaptations include mTOR activation, which stimulates HIF-1 
through downstream effectors,35–37 leading to altered cellular 
metabolism and angiogenesis.38 As a result, hypoxic cells   utilize 
anaerobic glycolysis for ATP production and rely less on oxida-
tive phosphorylation. With this shift to anaerobic   glycolysis, 
cells selectively alter gene expression to increase glucose 
transporters and glycolytic enzymes such as hexokinase, which 
catalyzes the phosphorylation of glucose in the first step of 
glycolysis. Maher et al recently showed that HIF-1 increases 
the expression of hexokinase.35 Conversely, hypoxic cells with 
altered siRNAs or mutations that are unable to activate HIF-1, 
have a corresponding decrease in hexokinase levels.35
The current study supports the hypothesis that hypoxic 
cells are targeted by blocking mTOR signaling with rapamy-
cin, leading to a corresponding reduction in tumor burden. 
The reduction in hypoxia observed from different doses of 
rapamycin treatment suggests that mTOR upregulation is 
involved in the survival mechanism used by retinoblastoma 
cells under hypoxic conditions. In the absence of mTOR, the 
regular process of HIF-1 proteosome-executing degradation 
continues,39 thus preventing hypoxic cells from having a cor-
responding increase in the levels of the enzymes and glucose 
transporters required to survive under anaerobic or low O2 
partial pressure conditions, making hypoxic cells less adept 
to rely on anaerobic metabolism.35 The current findings fur-
ther support the essential role the tumor microenvironment, 
notably hypoxia, plays in advanced tumor progression.
We  have  previously  shown  that  2-DG  and 
  2-fluorodeoxy-D-glucose (2-FDG) successfully kill the 
chemoresistant, hypoxic cell population and decrease tumor 
burden in the LHBETATAG transgenic mouse model of retino-
blastoma (work in progress for 2-FDG).15,17,32  These glycolytic 
inhibitors can be used in combination with chemotherapy and 
anti-angiogenic agents to have a synergistic effect on tumor 
burden.32 Since mTOR and HIF-1 upregulate the production 
of glycolytic enzymes, higher amounts of the competitive 
inhibitor, 2-DG, are essential to inhibit glycolysis. In fact, 
increased sensitivity of hypoxic cells to 2-DG is correlated 
to the expression of HIF in different tumor cell lines.40 It fol-
lows that mTOR inhibition should decrease this resistance to 
glycolytic inhibition found in tumor cells under hypoxia. Thus, 
blocking mTOR with rapamycin should not only interfere 
with the downstream upregulation of anaerobic metabolism 
but also cause hypoxic cells to become more susceptible to 
2-DG. Results from the current study further demonstrate that 
mTOR may play an essential role in either the cellular shift 
to anaerobic glycolysis or the anaerobic uptake of glucose. 
The dose effect response curve obtained for tumor burden 
and hypoxia following rapamycin treatment provides baseline 
data to consider combination therapies of mTOR and chemo-
therapy for vasculature targeting to treat retinoblastoma.
Angiogenesis has been highly correlated with tumor 
  proliferation and metastasis in a number of tumors.41–45   Protein 
synthesis for cell growth, proliferation, and angiogenesis is 
regulated by mTOR, which controls different signals from 
growth factor receptors to secure the cell with sufficient nutri-
ents and energy for cell growth. Cancer cells have been shown 
to have a dysregulation in the angiogenic pathways mediated by 
mTOR.46 Using the LHBETATAG mouse model of retinoblastoma, 
we have shown that anti-angiogenic therapy primarily targets 
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Figure 5 effect of rapamycin on mature blood vessels. neovessels and mature 
vessels were analyzed for the rapamycin dose with the highest impact on reducing 
tumor burden and hypoxia (ie, 3.33 mg/kg). Although the amount of both neo- and 
mature vessels decreased following treatment with rapamycin, only the amount of 
small-caliber, mature vessels decreased significantly (P = 0.015). DAPi stain (blue) 
for all the cell nuclei, endoglin stain (green) for neovessels, and α-sma stain (red) for 
mature blood vessels. Pictures were obtained at 200× high power field. 
Note: *Arrows indicate neovessels that do not overlap with mature vessels. 
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areas with high angiogenic activity, while having little to no 
effect in established mature blood vessels.30 We have also shown 
that the heterogeneity and spatial distribution of neovessels 
and mature vessels in ocular tumors may impact the efficacy 
of anti-angiogenic therapies, and may dictate the treatment 
modalities used.31,47 Other studies have shown that inhibition 
of mTOR can potentially inhibit angiogenesis by reducing 
VEGF-receptors (VEGFRs).48,49 VEGFR regulates angiogenic 
signaling in both endothelial cells and vascular pericytes, medi-
ating tumor proliferation.49,50 In the current study, the number 
of mature blood vessels significantly decreased following 
treatment with rapamycin, whereas the number of neovessels 
remained stable following treatment. These results suggest 
that rapamycin affected pericytes, having little or no effect on 
endothelial cells. This drug may have had an indirect effect on 
vascular pericytes by mediating the angiogenic signaling from 
VEGFR in the tumor microenvironment. In addition, the use of 
DMSO as the vehicle control may cause nonapparent toxicities 
on the tumors, affecting the overall effects of angiogenesis.51–53 
Since anti-angiogenic therapy (ie, anecortave acetate and com-
bretastatin) has no effect in the established, pericyte protected 
mature blood vessels that are present in advanced LHBETATAG 
retinal tumors,30 rapamycin may be an alternative treatment 
modulator to enhance the effects of anti-angiogenic agents and, 
thus, their modulation as adjuvant therapies in the treatment of 
retinoblastoma.17,26,30
In conclusion, we have shown that the mTOR inhibitor 
rapamycin led to greater tumor control and decreased the 
amount of hypoxic regions in the LHBETATAG mouse model 
for retinoblastoma. The use of rapamycin as an mTOR 
inhibitor in a preclinical trial has several benefits. Rapamycin 
is commercially available, has been extensively studied in 
human clinical trials, and has a unique preparation (topical 
delivery).54–58 We believe that mTOR is a potential target in 
retinoblastoma and its modulation may allow a synergistic 
impact on tumor burden control in combination with standard 
treatment modalities (eg, chemotherapy) and other adjuvant 
therapies (eg, glycolytic inhibitors and anti-angiogenic 
agents) to treat retinoblastoma tumors. Future studies should 
include testing the compatibility of different treatment dose 
and schedule combinations for optimal retinoblastoma tumor 
burden control.
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